Short answer
Zimmer Biomet (ZBH) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 results for quarter ended September 30, 2026 released November 4, 2026.
Zimmer Biomet 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 results for quarter ended September 30, 2026 released November 4, 2026
- Detailed financial results and management commentary available in Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- Q3 net sales $2.063B, up 3.1% reported and 3.7% constant currency, signaling improving underlying demand
- Adjusted diluted EPS $1.90, flat year over year, while GAAP diluted EPS fell 13.8% to $1.00
- Growth concentrated in Hips, S.E.T., and Technology & Data, Bone Cement and Surgical, while Knees declined 3.1%
- Full-year organic constant-currency sales guidance raised to 3.0%-3.5% from 2.25%-3.25%
- Adjusted diluted EPS guidance increased to $8.50-$8.60 from $8.47-$8.59
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Zimmer Biomet 8-K filings
Get the next ZBH 8-K as it lands
Follow ZBH for push alerts, or ask the research agent what this filing means.